#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Reduced Parietal Alpha Power and Psychotic Symptoms: Test-Retest Reliability of Resting-State Magnetoencephalography in Schizophrenia and Healthy Controls Background: Despite increased reporting of resting-state magnetoencephalography (MEG), reliability of those measures remains scarce and predominately reported in healthy controls (HC).
1-1	0-7	Reduced	_
1-2	8-16	Parietal	_
1-3	17-22	Alpha	_
1-4	23-28	Power	_
1-5	29-32	and	_
1-6	33-42	Psychotic	_
1-7	43-51	Symptoms	_
1-8	52-53	:	_
1-9	54-65	Test-Retest	_
1-10	66-77	Reliability	_
1-11	78-80	of	_
1-12	81-94	Resting-State	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-13	95-117	Magnetoencephalography	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-14	118-120	in	_
1-15	121-134	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-16	135-138	and	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-17	139-146	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
1-18	147-155	Controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
1-19	156-166	Background	_
1-20	167-168	:	_
1-21	169-176	Despite	_
1-22	177-186	increased	_
1-23	187-196	reporting	_
1-24	197-199	of	_
1-25	200-213	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
1-26	214-236	magnetoencephalography	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
1-27	237-238	(	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
1-28	239-242	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
1-29	243-244	)	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
1-30	245-246	,	_
1-31	247-258	reliability	_
1-32	259-261	of	_
1-33	262-267	those	_
1-34	268-276	measures	_
1-35	277-284	remains	_
1-36	285-291	scarce	_
1-37	292-295	and	_
1-38	296-309	predominately	_
1-39	310-318	reported	_
1-40	319-321	in	_
1-41	322-329	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
1-42	330-338	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
1-43	339-340	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
1-44	341-343	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
1-45	344-345	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
1-46	346-347	.	_

Text=As such, there is limited knowledge on MEG resting-state reliability in schizophrenia (SZ).
2-1	348-350	As	_
2-2	351-355	such	_
2-3	356-357	,	_
2-4	358-363	there	_
2-5	364-366	is	_
2-6	367-374	limited	_
2-7	375-384	knowledge	_
2-8	385-387	on	_
2-9	388-391	MEG	_
2-10	392-405	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-11	406-417	reliability	_
2-12	418-420	in	_
2-13	421-434	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-14	435-436	(	_
2-15	437-439	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
2-16	440-441	)	_
2-17	442-443	.	_

Text=Methods: To address test-retest reliability in psychosis, a reproducibility study of 26 participants (13-SZ, 13-HC) was performed.
3-1	444-451	Methods	_
3-2	452-453	:	_
3-3	454-456	To	_
3-4	457-464	address	_
3-5	465-476	test-retest	_
3-6	477-488	reliability	_
3-7	489-491	in	_
3-8	492-501	psychosis	_
3-9	502-503	,	_
3-10	504-505	a	_
3-11	506-521	reproducibility	_
3-12	522-527	study	_
3-13	528-530	of	_
3-14	531-533	26	_
3-15	534-546	participants	_
3-16	547-548	(	_
3-17	549-554	13-SZ	_
3-18	555-556	,	_
3-19	557-562	13-HC	_
3-20	563-564	)	_
3-21	565-568	was	_
3-22	569-578	performed	_
3-23	579-580	.	_

Text=We collected eyes open and eyes closed resting-state data during 4 separate instances (2 Visits, 2 runs per visit) to estimate spectral power reliability (power, normalized power, alpha reactivity) across one hour and one week.
4-1	581-583	We	_
4-2	584-593	collected	_
4-3	594-598	eyes	_
4-4	599-603	open	_
4-5	604-607	and	_
4-6	608-612	eyes	_
4-7	613-619	closed	_
4-8	620-633	resting-state	_
4-9	634-638	data	_
4-10	639-645	during	_
4-11	646-647	4	_
4-12	648-656	separate	_
4-13	657-666	instances	_
4-14	667-668	(	_
4-15	669-670	2	_
4-16	671-677	Visits	_
4-17	678-679	,	_
4-18	680-681	2	_
4-19	682-686	runs	_
4-20	687-690	per	_
4-21	691-696	visit	_
4-22	697-698	)	_
4-23	699-701	to	_
4-24	702-710	estimate	_
4-25	711-719	spectral	_
4-26	720-725	power	_
4-27	726-737	reliability	_
4-28	738-739	(	_
4-29	740-745	power	_
4-30	746-747	,	_
4-31	748-758	normalized	_
4-32	759-764	power	_
4-33	765-766	,	_
4-34	767-772	alpha	_
4-35	773-783	reactivity	_
4-36	784-785	)	_
4-37	786-792	across	_
4-38	793-796	one	_
4-39	797-801	hour	_
4-40	802-805	and	_
4-41	806-809	one	_
4-42	810-814	week	_
4-43	815-816	.	_

Text=Intraclass correlation coefficients (ICCs) were calculated.
5-1	817-827	Intraclass	_
5-2	828-839	correlation	_
5-3	840-852	coefficients	_
5-4	853-854	(	_
5-5	855-859	ICCs	_
5-6	860-861	)	_
5-7	862-866	were	_
5-8	867-877	calculated	_
5-9	878-879	.	_

Text=For source modeling, we applied an anatomically constrained linear estimation inverse model known as dynamic statistical parametric mapping (MNE dSPM) and source-based connectivity using the weighted phase lag index.
6-1	880-883	For	_
6-2	884-890	source	_
6-3	891-899	modeling	_
6-4	900-901	,	_
6-5	902-904	we	_
6-6	905-912	applied	_
6-7	913-915	an	_
6-8	916-928	anatomically	_
6-9	929-940	constrained	_
6-10	941-947	linear	_
6-11	948-958	estimation	_
6-12	959-966	inverse	_
6-13	967-972	model	_
6-14	973-978	known	_
6-15	979-981	as	_
6-16	982-989	dynamic	_
6-17	990-1001	statistical	_
6-18	1002-1012	parametric	_
6-19	1013-1020	mapping	_
6-20	1021-1022	(	_
6-21	1023-1026	MNE	_
6-22	1027-1031	dSPM	_
6-23	1032-1033	)	_
6-24	1034-1037	and	_
6-25	1038-1050	source-based	_
6-26	1051-1063	connectivity	_
6-27	1064-1069	using	_
6-28	1070-1073	the	_
6-29	1074-1082	weighted	_
6-30	1083-1088	phase	_
6-31	1089-1092	lag	_
6-32	1093-1098	index	_
6-33	1099-1100	.	_

Text=Results: Across one week there was excellent test-retest reliability in global spectral measures in theta-gamma bands (HC ICCAvg=0.87, SZ ICCAvg=0.87), regional spectral measures in all bands (HC ICCAvg=0.86, SZ ICCAvg=0.80), and parietal alpha measures (HC ICCAvg=0.90, SZ ICCAvg=0.84).
7-1	1101-1108	Results	_
7-2	1109-1110	:	_
7-3	1111-1117	Across	_
7-4	1118-1121	one	_
7-5	1122-1126	week	_
7-6	1127-1132	there	_
7-7	1133-1136	was	_
7-8	1137-1146	excellent	_
7-9	1147-1158	test-retest	_
7-10	1159-1170	reliability	_
7-11	1171-1173	in	_
7-12	1174-1180	global	_
7-13	1181-1189	spectral	_
7-14	1190-1198	measures	_
7-15	1199-1201	in	_
7-16	1202-1213	theta-gamma	_
7-17	1214-1219	bands	_
7-18	1220-1221	(	_
7-19	1222-1224	HC	_
7-20	1225-1236	ICCAvg=0.87	_
7-21	1237-1238	,	_
7-22	1239-1241	SZ	_
7-23	1242-1253	ICCAvg=0.87	_
7-24	1254-1255	)	_
7-25	1256-1257	,	_
7-26	1258-1266	regional	_
7-27	1267-1275	spectral	_
7-28	1276-1284	measures	_
7-29	1285-1287	in	_
7-30	1288-1291	all	_
7-31	1292-1297	bands	_
7-32	1298-1299	(	_
7-33	1300-1302	HC	_
7-34	1303-1314	ICCAvg=0.86	_
7-35	1315-1316	,	_
7-36	1317-1319	SZ	_
7-37	1320-1331	ICCAvg=0.80	_
7-38	1332-1333	)	_
7-39	1334-1335	,	_
7-40	1336-1339	and	_
7-41	1340-1348	parietal	_
7-42	1349-1354	alpha	_
7-43	1355-1363	measures	_
7-44	1364-1365	(	_
7-45	1366-1368	HC	_
7-46	1369-1380	ICCAvg=0.90	_
7-47	1381-1382	,	_
7-48	1383-1385	SZ	_
7-49	1386-1397	ICCAvg=0.84	_
7-50	1398-1399	)	_
7-51	1400-1401	.	_

Text=Conversely, functional connectivity had poor reliability, as did source spectral power across one hour for SZ.
8-1	1402-1412	Conversely	_
8-2	1413-1414	,	_
8-3	1415-1425	functional	_
8-4	1426-1438	connectivity	_
8-5	1439-1442	had	_
8-6	1443-1447	poor	_
8-7	1448-1459	reliability	_
8-8	1460-1461	,	_
8-9	1462-1464	as	_
8-10	1465-1468	did	_
8-11	1469-1475	source	_
8-12	1476-1484	spectral	_
8-13	1485-1490	power	_
8-14	1491-1497	across	_
8-15	1498-1501	one	_
8-16	1502-1506	hour	_
8-17	1507-1510	for	_
8-18	1511-1513	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
8-19	1514-1515	.	_

Text=Relative to HC, SZ also had reduced parietal alpha normalized power during eyes closed only, reduced alpha reactivity, and an association between higher PANSS positive scores and lower parietal alpha power.
9-1	1516-1524	Relative	_
9-2	1525-1527	to	_
9-3	1528-1530	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-4	1531-1532	,	_
9-5	1533-1535	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-6	1536-1540	also	_
9-7	1541-1544	had	_
9-8	1545-1552	reduced	_
9-9	1553-1561	parietal	_
9-10	1562-1567	alpha	_
9-11	1568-1578	normalized	_
9-12	1579-1584	power	_
9-13	1585-1591	during	_
9-14	1592-1596	eyes	_
9-15	1597-1603	closed	_
9-16	1604-1608	only	_
9-17	1609-1610	,	_
9-18	1611-1618	reduced	_
9-19	1619-1624	alpha	_
9-20	1625-1635	reactivity	_
9-21	1636-1637	,	_
9-22	1638-1641	and	_
9-23	1642-1644	an	_
9-24	1645-1656	association	_
9-25	1657-1664	between	_
9-26	1665-1671	higher	_
9-27	1672-1677	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
9-28	1678-1686	positive	_
9-29	1687-1693	scores	_
9-30	1694-1697	and	_
9-31	1698-1703	lower	_
9-32	1704-1712	parietal	_
9-33	1713-1718	alpha	_
9-34	1719-1724	power	_
9-35	1725-1726	.	_

Text=Conclusions: There was excellent to good test-retest reliability in most MEG spectral measures with a few exceptions in the schizophrenia patient group.
10-1	1727-1738	Conclusions	_
10-2	1739-1740	:	_
10-3	1741-1746	There	_
10-4	1747-1750	was	_
10-5	1751-1760	excellent	_
10-6	1761-1763	to	_
10-7	1764-1768	good	_
10-8	1769-1780	test-retest	_
10-9	1781-1792	reliability	_
10-10	1793-1795	in	_
10-11	1796-1800	most	_
10-12	1801-1804	MEG	_
10-13	1805-1813	spectral	_
10-14	1814-1822	measures	_
10-15	1823-1827	with	_
10-16	1828-1829	a	_
10-17	1830-1833	few	_
10-18	1834-1844	exceptions	_
10-19	1845-1847	in	_
10-20	1848-1851	the	_
10-21	1852-1865	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-22	1866-1873	patient	_
10-23	1874-1879	group	_
10-24	1880-1881	.	_

Text=Overall, these findings encourage the use of resting-state MEG while emphasizing the importance of determining reliability in clinical populations.
11-1	1882-1889	Overall	_
11-2	1890-1891	,	_
11-3	1892-1897	these	_
11-4	1898-1906	findings	_
11-5	1907-1916	encourage	_
11-6	1917-1920	the	_
11-7	1921-1924	use	_
11-8	1925-1927	of	_
11-9	1928-1941	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
11-10	1942-1945	MEG	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
11-11	1946-1951	while	_
11-12	1952-1963	emphasizing	_
11-13	1964-1967	the	_
11-14	1968-1978	importance	_
11-15	1979-1981	of	_
11-16	1982-1993	determining	_
11-17	1994-2005	reliability	_
11-18	2006-2008	in	_
11-19	2009-2017	clinical	_
11-20	2018-2029	populations	_
11-21	2030-2031	.	_

Text=Materials and Methods Participants The current study included 13 individuals diagnosed with schizophrenia (SZ) and 13 healthy controls (HC), age and gender matched, Table 1.
12-1	2032-2041	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	2042-2045	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	2046-2053	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-4	2054-2066	Participants	_
12-5	2067-2070	The	_
12-6	2071-2078	current	_
12-7	2079-2084	study	_
12-8	2085-2093	included	_
12-9	2094-2096	13	_
12-10	2097-2108	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
12-11	2109-2118	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-12	2119-2123	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-13	2124-2137	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-14	2138-2139	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-15	2140-2142	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-16	2143-2144	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-17	2145-2148	and	_
12-18	2149-2151	13	_
12-19	2152-2159	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
12-20	2160-2168	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
12-21	2169-2170	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
12-22	2171-2173	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
12-23	2174-2175	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
12-24	2176-2177	,	_
12-25	2178-2181	age	_
12-26	2182-2185	and	_
12-27	2186-2192	gender	_
12-28	2193-2200	matched	_
12-29	2201-2202	,	_
12-30	2203-2208	Table	_
12-31	2209-2210	1	_
12-32	2211-2212	.	_

Text=Informed consent was obtained from all participants according to institutional guidelines.
13-1	2213-2221	Informed	_
13-2	2222-2229	consent	_
13-3	2230-2233	was	_
13-4	2234-2242	obtained	_
13-5	2243-2247	from	_
13-6	2248-2251	all	_
13-7	2252-2264	participants	_
13-8	2265-2274	according	_
13-9	2275-2277	to	_
13-10	2278-2291	institutional	_
13-11	2292-2302	guidelines	_
13-12	2303-2304	.	_

Text=The study was approved by the University of New Mexico Health Sciences Center Human Research Review Committee.
14-1	2305-2308	The	_
14-2	2309-2314	study	_
14-3	2315-2318	was	_
14-4	2319-2327	approved	_
14-5	2328-2330	by	_
14-6	2331-2334	the	_
14-7	2335-2345	University	_
14-8	2346-2348	of	_
14-9	2349-2352	New	_
14-10	2353-2359	Mexico	_
14-11	2360-2366	Health	_
14-12	2367-2375	Sciences	_
14-13	2376-2382	Center	_
14-14	2383-2388	Human	_
14-15	2389-2397	Research	_
14-16	2398-2404	Review	_
14-17	2405-2414	Committee	_
14-18	2415-2416	.	_

Text=All participants were within 21–49 years of age with no history of neurological disorder (e.g.
15-1	2417-2420	All	_
15-2	2421-2433	participants	_
15-3	2434-2438	were	_
15-4	2439-2445	within	_
15-5	2446-2451	21–49	_
15-6	2452-2457	years	_
15-7	2458-2460	of	_
15-8	2461-2464	age	_
15-9	2465-2469	with	_
15-10	2470-2472	no	_
15-11	2473-2480	history	_
15-12	2481-2483	of	_
15-13	2484-2496	neurological	_
15-14	2497-2505	disorder	_
15-15	2506-2507	(	_
15-16	2508-2511	e.g	_
15-17	2512-2513	.	_

Text=epilepsy), no history of major head trauma (loss of consciousness> 5 min), no current substance abuse diagnosis (excluding nicotine), no current dependence/abuse of PCP/amphetamine/cocaine within the past 12 months, and were not currently on mood stabilizers such as lithium or valproic acid.
16-1	2514-2522	epilepsy	_
16-2	2523-2524	)	_
16-3	2525-2526	,	_
16-4	2527-2529	no	_
16-5	2530-2537	history	_
16-6	2538-2540	of	_
16-7	2541-2546	major	_
16-8	2547-2551	head	_
16-9	2552-2558	trauma	_
16-10	2559-2560	(	_
16-11	2561-2565	loss	_
16-12	2566-2568	of	_
16-13	2569-2582	consciousness	_
16-14	2583-2584	>	_
16-15	2585-2586	5	_
16-16	2587-2590	min	_
16-17	2591-2592	)	_
16-18	2593-2594	,	_
16-19	2595-2597	no	_
16-20	2598-2605	current	_
16-21	2606-2615	substance	_
16-22	2616-2621	abuse	_
16-23	2622-2631	diagnosis	_
16-24	2632-2633	(	_
16-25	2634-2643	excluding	_
16-26	2644-2652	nicotine	_
16-27	2653-2654	)	_
16-28	2655-2656	,	_
16-29	2657-2659	no	_
16-30	2660-2667	current	_
16-31	2668-2684	dependence/abuse	_
16-32	2685-2687	of	_
16-33	2688-2711	PCP/amphetamine/cocaine	_
16-34	2712-2718	within	_
16-35	2719-2722	the	_
16-36	2723-2727	past	_
16-37	2728-2730	12	_
16-38	2731-2737	months	_
16-39	2738-2739	,	_
16-40	2740-2743	and	_
16-41	2744-2748	were	_
16-42	2749-2752	not	_
16-43	2753-2762	currently	_
16-44	2763-2765	on	_
16-45	2766-2770	mood	_
16-46	2771-2782	stabilizers	_
16-47	2783-2787	such	_
16-48	2788-2790	as	_
16-49	2791-2798	lithium	_
16-50	2799-2801	or	_
16-51	2802-2810	valproic	_
16-52	2811-2815	acid	_
16-53	2816-2817	.	_

Text=HC had IQ scores within the normal range and no history of developmental delays or neurological or psychiatric disorders based on the Structured Clinical Interview for DSM-IV-Non-patient (SCIDNP).
17-1	2818-2820	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-2	2821-2824	had	_
17-3	2825-2827	IQ	_
17-4	2828-2834	scores	_
17-5	2835-2841	within	_
17-6	2842-2845	the	_
17-7	2846-2852	normal	_
17-8	2853-2858	range	_
17-9	2859-2862	and	_
17-10	2863-2865	no	_
17-11	2866-2873	history	_
17-12	2874-2876	of	_
17-13	2877-2890	developmental	_
17-14	2891-2897	delays	_
17-15	2898-2900	or	_
17-16	2901-2913	neurological	_
17-17	2914-2916	or	_
17-18	2917-2928	psychiatric	_
17-19	2929-2938	disorders	_
17-20	2939-2944	based	_
17-21	2945-2947	on	_
17-22	2948-2951	the	_
17-23	2952-2962	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-24	2963-2971	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-25	2972-2981	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-26	2982-2985	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-27	2986-3004	DSM-IV-Non-patient	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-28	3005-3006	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-29	3007-3013	SCIDNP	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-30	3014-3015	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-31	3016-3017	.	_

Text=HCs also did not have a family history of a psychotic disorder in first-degree relatives or a history of more than 1 lifetime depressive episode.
18-1	3018-3021	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
18-2	3022-3026	also	_
18-3	3027-3030	did	_
18-4	3031-3034	not	_
18-5	3035-3039	have	_
18-6	3040-3041	a	_
18-7	3042-3048	family	_
18-8	3049-3056	history	_
18-9	3057-3059	of	_
18-10	3060-3061	a	_
18-11	3062-3071	psychotic	_
18-12	3072-3080	disorder	_
18-13	3081-3083	in	_
18-14	3084-3096	first-degree	_
18-15	3097-3106	relatives	_
18-16	3107-3109	or	_
18-17	3110-3111	a	_
18-18	3112-3119	history	_
18-19	3120-3122	of	_
18-20	3123-3127	more	_
18-21	3128-3132	than	_
18-22	3133-3134	1	_
18-23	3135-3143	lifetime	_
18-24	3144-3154	depressive	_
18-25	3155-3162	episode	_
18-26	3163-3164	.	_

Text=Participants with schizophrenia were confirmed to have a DSM-IV-TR diagnosis of schizophrenia with the Structured Clinical Interview for DSM-IV-Patient (SCID-IP) and retrospective clinical stability.
19-1	3165-3177	Participants	_
19-2	3178-3182	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-3	3183-3196	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-4	3197-3201	were	_
19-5	3202-3211	confirmed	_
19-6	3212-3214	to	_
19-7	3215-3219	have	_
19-8	3220-3221	a	_
19-9	3222-3231	DSM-IV-TR	_
19-10	3232-3241	diagnosis	_
19-11	3242-3244	of	_
19-12	3245-3258	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-13	3259-3263	with	_
19-14	3264-3267	the	_
19-15	3268-3278	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-16	3279-3287	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-17	3288-3297	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-18	3298-3301	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-19	3302-3316	DSM-IV-Patient	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-20	3317-3318	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-21	3319-3326	SCID-IP	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-22	3327-3328	)	_
19-23	3329-3332	and	_
19-24	3333-3346	retrospective	_
19-25	3347-3355	clinical	_
19-26	3356-3365	stability	_
19-27	3366-3367	.	_

Text=Participants were not excluded for nicotine use, however, they were not allowed to smoke within 1 hour of the MEG session or be more than 5 hours from their previous cigarette to avoid confounds of acute nicotine exposure or withdrawal.
20-1	3368-3380	Participants	_
20-2	3381-3385	were	_
20-3	3386-3389	not	_
20-4	3390-3398	excluded	_
20-5	3399-3402	for	_
20-6	3403-3411	nicotine	_
20-7	3412-3415	use	_
20-8	3416-3417	,	_
20-9	3418-3425	however	_
20-10	3426-3427	,	_
20-11	3428-3432	they	_
20-12	3433-3437	were	_
20-13	3438-3441	not	_
20-14	3442-3449	allowed	_
20-15	3450-3452	to	_
20-16	3453-3458	smoke	_
20-17	3459-3465	within	_
20-18	3466-3467	1	_
20-19	3468-3472	hour	_
20-20	3473-3475	of	_
20-21	3476-3479	the	_
20-22	3480-3483	MEG	_
20-23	3484-3491	session	_
20-24	3492-3494	or	_
20-25	3495-3497	be	_
20-26	3498-3502	more	_
20-27	3503-3507	than	_
20-28	3508-3509	5	_
20-29	3510-3515	hours	_
20-30	3516-3520	from	_
20-31	3521-3526	their	_
20-32	3527-3535	previous	_
20-33	3536-3545	cigarette	_
20-34	3546-3548	to	_
20-35	3549-3554	avoid	_
20-36	3555-3564	confounds	_
20-37	3565-3567	of	_
20-38	3568-3573	acute	_
20-39	3574-3582	nicotine	_
20-40	3583-3591	exposure	_
20-41	3592-3594	or	_
20-42	3595-3605	withdrawal	_
20-43	3606-3607	.	_

Text=The following assessments were collected in SZ participants and reported in Table 1: Wechsler Test of Adult Reading (WTAR), Standard and Predicted (premorbid) IQ, Positive and Negative Syndrome Scale (PANSS), antipsychotic medication dose information, and duration of illness.
21-1	3608-3611	The	_
21-2	3612-3621	following	_
21-3	3622-3633	assessments	_
21-4	3634-3638	were	_
21-5	3639-3648	collected	_
21-6	3649-3651	in	_
21-7	3652-3654	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
21-8	3655-3667	participants	_
21-9	3668-3671	and	_
21-10	3672-3680	reported	_
21-11	3681-3683	in	_
21-12	3684-3689	Table	_
21-13	3690-3691	1	_
21-14	3692-3693	:	_
21-15	3694-3702	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
21-16	3703-3707	Test	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
21-17	3708-3710	of	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
21-18	3711-3716	Adult	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
21-19	3717-3724	Reading	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
21-20	3725-3726	(	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
21-21	3727-3731	WTAR	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
21-22	3732-3733	)	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
21-23	3734-3735	,	_
21-24	3736-3744	Standard	http://maven.renci.org/NeuroBridge/neurobridge#StandardDeviationMeasure
21-25	3745-3748	and	http://maven.renci.org/NeuroBridge/neurobridge#StandardDeviationMeasure
21-26	3749-3758	Predicted	http://maven.renci.org/NeuroBridge/neurobridge#StandardDeviationMeasure
21-27	3759-3760	(	http://maven.renci.org/NeuroBridge/neurobridge#StandardDeviationMeasure
21-28	3761-3770	premorbid	_
21-29	3771-3772	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-30	3773-3775	IQ	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-31	3776-3777	,	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-32	3778-3786	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-33	3787-3790	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-34	3791-3799	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-35	3800-3808	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-36	3809-3814	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-37	3815-3816	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-38	3817-3822	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-39	3823-3824	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-40	3825-3826	,	_
21-41	3827-3840	antipsychotic	_
21-42	3841-3851	medication	_
21-43	3852-3856	dose	_
21-44	3857-3868	information	_
21-45	3869-3870	,	_
21-46	3871-3874	and	_
21-47	3875-3883	duration	_
21-48	3884-3886	of	_
21-49	3887-3894	illness	_
21-50	3895-3896	.	_

Text=PANSS scores were determined for each visit.
22-1	3897-3902	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-2	3903-3909	scores	_
22-3	3910-3914	were	_
22-4	3915-3925	determined	_
22-5	3926-3929	for	_
22-6	3930-3934	each	_
22-7	3935-3940	visit	_
22-8	3941-3942	.	_

Text=Antipsychotic medication was converted to olanzapine equivalents for comparison between medication.
23-1	3943-3956	Antipsychotic	_
23-2	3957-3967	medication	_
23-3	3968-3971	was	_
23-4	3972-3981	converted	_
23-5	3982-3984	to	_
23-6	3985-3995	olanzapine	_
23-7	3996-4007	equivalents	_
23-8	4008-4011	for	_
23-9	4012-4022	comparison	_
23-10	4023-4030	between	_
23-11	4031-4041	medication	_
23-12	4042-4043	.	_

Text=Duration of illness was calculated by subtracting age at onset of psychotic symptoms from current age.
24-1	4044-4052	Duration	_
24-2	4053-4055	of	_
24-3	4056-4063	illness	_
24-4	4064-4067	was	_
24-5	4068-4078	calculated	_
24-6	4079-4081	by	_
24-7	4082-4093	subtracting	_
24-8	4094-4097	age	_
24-9	4098-4100	at	_
24-10	4101-4106	onset	_
24-11	4107-4109	of	_
24-12	4110-4119	psychotic	_
24-13	4120-4128	symptoms	_
24-14	4129-4133	from	_
24-15	4134-4141	current	_
24-16	4142-4145	age	_
24-17	4146-4147	.	_

Text=MEG Behavioral Tasks All participants had two visits across 7 days [HC=7.54 days ±60 minutes, SZ=7.84 days ±51 minutes].
25-1	4148-4151	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
25-2	4152-4162	Behavioral	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
25-3	4163-4168	Tasks	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
25-4	4169-4172	All	_
25-5	4173-4185	participants	_
25-6	4186-4189	had	_
25-7	4190-4193	two	_
25-8	4194-4200	visits	_
25-9	4201-4207	across	_
25-10	4208-4209	7	_
25-11	4210-4214	days	_
25-12	4215-4216	[	_
25-13	4217-4224	HC=7.54	_
25-14	4225-4229	days	_
25-15	4230-4233	±60	_
25-16	4234-4241	minutes	_
25-17	4242-4243	,	_
25-18	4244-4251	SZ=7.84	_
25-19	4252-4256	days	_
25-20	4257-4260	±51	_
25-21	4261-4268	minutes	_
25-22	4269-4270	]	_
25-23	4271-4272	.	_

Text=Time of day between visits was matched to take into account circadian rhythm.
26-1	4273-4277	Time	_
26-2	4278-4280	of	_
26-3	4281-4284	day	_
26-4	4285-4292	between	_
26-5	4293-4299	visits	_
26-6	4300-4303	was	_
26-7	4304-4311	matched	_
26-8	4312-4314	to	_
26-9	4315-4319	take	_
26-10	4320-4324	into	_
26-11	4325-4332	account	_
26-12	4333-4342	circadian	_
26-13	4343-4349	rhythm	_
26-14	4350-4351	.	_

Text=Each visit began with a 10-minute rest task (referred to as Rest10) and ended with a 4-minute rest task (referred to as Rest4), see Figure 1.
27-1	4352-4356	Each	_
27-2	4357-4362	visit	_
27-3	4363-4368	began	_
27-4	4369-4373	with	_
27-5	4374-4375	a	_
27-6	4376-4385	10-minute	_
27-7	4386-4390	rest	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-8	4391-4395	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-9	4396-4397	(	_
27-10	4398-4406	referred	_
27-11	4407-4409	to	_
27-12	4410-4412	as	_
27-13	4413-4419	Rest10	_
27-14	4420-4421	)	_
27-15	4422-4425	and	_
27-16	4426-4431	ended	_
27-17	4432-4436	with	_
27-18	4437-4438	a	_
27-19	4439-4447	4-minute	_
27-20	4448-4452	rest	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-21	4453-4457	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-22	4458-4459	(	_
27-23	4460-4468	referred	_
27-24	4469-4471	to	_
27-25	4472-4474	as	_
27-26	4475-4480	Rest4	_
27-27	4481-4482	)	_
27-28	4483-4484	,	_
27-29	4485-4488	see	_
27-30	4489-4495	Figure	_
27-31	4496-4497	1	_
27-32	4498-4499	.	_

Text=No responses were required from the participant; however, participants were instructed to attend the instructions for prompts to close their eyes or fixate on a white cross.
28-1	4500-4502	No	_
28-2	4503-4512	responses	_
28-3	4513-4517	were	_
28-4	4518-4526	required	_
28-5	4527-4531	from	_
28-6	4532-4535	the	_
28-7	4536-4547	participant	_
28-8	4548-4549	;	_
28-9	4550-4557	however	_
28-10	4558-4559	,	_
28-11	4560-4572	participants	_
28-12	4573-4577	were	_
28-13	4578-4588	instructed	_
28-14	4589-4591	to	_
28-15	4592-4598	attend	_
28-16	4599-4602	the	_
28-17	4603-4615	instructions	_
28-18	4616-4619	for	_
28-19	4620-4627	prompts	_
28-20	4628-4630	to	_
28-21	4631-4636	close	_
28-22	4637-4642	their	_
28-23	4643-4647	eyes	_
28-24	4648-4650	or	_
28-25	4651-4657	fixate	_
28-26	4658-4660	on	_
28-27	4661-4662	a	_
28-28	4663-4668	white	_
28-29	4669-4674	cross	_
28-30	4675-4676	.	_

Text=Each task alternated between EC and EO.
29-1	4677-4681	Each	_
29-2	4682-4686	task	_
29-3	4687-4697	alternated	_
29-4	4698-4705	between	_
29-5	4706-4708	EC	_
29-6	4709-4712	and	_
29-7	4713-4715	EO	_
29-8	4716-4717	.	_

Text=In total, resting-state activity was recorded 4 separate times with 14 minutes of EO and 14 minutes of EC.
30-1	4718-4720	In	_
30-2	4721-4726	total	_
30-3	4727-4728	,	_
30-4	4729-4742	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-5	4743-4751	activity	_
30-6	4752-4755	was	_
30-7	4756-4764	recorded	_
30-8	4765-4766	4	_
30-9	4767-4775	separate	_
30-10	4776-4781	times	_
30-11	4782-4786	with	_
30-12	4787-4789	14	_
30-13	4790-4797	minutes	_
30-14	4798-4800	of	_
30-15	4801-4803	EO	_
30-16	4804-4807	and	_
30-17	4808-4810	14	_
30-18	4811-4818	minutes	_
30-19	4819-4821	of	_
30-20	4822-4824	EC	_
30-21	4825-4826	.	_

Text=MEG Data Acquisition MEG data were collected in a magnetically shielded room (Vacuumschmelze – Ak3B) at the Mind Research Network in Albuquerque, New Mexico using a 306-channel whole-head MEG system (Elekta Neuromag) with a sampling rate of 1000 Hz and an antialiasing filter with a passband of 0.1–330 Hz.
31-1	4827-4830	MEG	_
31-2	4831-4835	Data	_
31-3	4836-4847	Acquisition	_
31-4	4848-4851	MEG	_
31-5	4852-4856	data	_
31-6	4857-4861	were	_
31-7	4862-4871	collected	_
31-8	4872-4874	in	_
31-9	4875-4876	a	_
31-10	4877-4889	magnetically	_
31-11	4890-4898	shielded	_
31-12	4899-4903	room	_
31-13	4904-4905	(	_
31-14	4906-4920	Vacuumschmelze	_
31-15	4921-4922	–	_
31-16	4923-4927	Ak3B	_
31-17	4928-4929	)	_
31-18	4930-4932	at	_
31-19	4933-4936	the	_
31-20	4937-4941	Mind	_
31-21	4942-4950	Research	_
31-22	4951-4958	Network	_
31-23	4959-4961	in	_
31-24	4962-4973	Albuquerque	_
31-25	4974-4975	,	_
31-26	4976-4979	New	_
31-27	4980-4986	Mexico	_
31-28	4987-4992	using	_
31-29	4993-4994	a	_
31-30	4995-5006	306-channel	_
31-31	5007-5017	whole-head	_
31-32	5018-5021	MEG	_
31-33	5022-5028	system	_
31-34	5029-5030	(	_
31-35	5031-5037	Elekta	_
31-36	5038-5046	Neuromag	_
31-37	5047-5048	)	_
31-38	5049-5053	with	_
31-39	5054-5055	a	_
31-40	5056-5064	sampling	_
31-41	5065-5069	rate	_
31-42	5070-5072	of	_
31-43	5073-5077	1000	_
31-44	5078-5080	Hz	_
31-45	5081-5084	and	_
31-46	5085-5087	an	_
31-47	5088-5100	antialiasing	_
31-48	5101-5107	filter	_
31-49	5108-5112	with	_
31-50	5113-5114	a	_
31-51	5115-5123	passband	_
31-52	5124-5126	of	_
31-53	5127-5134	0.1–330	_
31-54	5135-5137	Hz	_
31-55	5138-5139	.	_

Text=Prior to data acquisition, four electromagnetic coils were placed on the participant ’ s mastoid bone and upper forehead, along with electro-oculogram and electrocardiogram channels.
32-1	5140-5145	Prior	_
32-2	5146-5148	to	_
32-3	5149-5153	data	_
32-4	5154-5165	acquisition	_
32-5	5166-5167	,	_
32-6	5168-5172	four	_
32-7	5173-5188	electromagnetic	_
32-8	5189-5194	coils	_
32-9	5195-5199	were	_
32-10	5200-5206	placed	_
32-11	5207-5209	on	_
32-12	5210-5213	the	_
32-13	5214-5225	participant	_
32-14	5226-5227	’	_
32-15	5228-5229	s	_
32-16	5230-5237	mastoid	_
32-17	5238-5242	bone	_
32-18	5243-5246	and	_
32-19	5247-5252	upper	_
32-20	5253-5261	forehead	_
32-21	5262-5263	,	_
32-22	5264-5269	along	_
32-23	5270-5274	with	_
32-24	5275-5292	electro-oculogram	_
32-25	5293-5296	and	_
32-26	5297-5314	electrocardiogram	_
32-27	5315-5323	channels	_
32-28	5324-5325	.	_

Text=The location of the coils were registered to the nasion and preauricular points using three-dimensional digitization equipment (Polhemus FastTrack).
33-1	5326-5329	The	_
33-2	5330-5338	location	_
33-3	5339-5341	of	_
33-4	5342-5345	the	_
33-5	5346-5351	coils	_
33-6	5352-5356	were	_
33-7	5357-5367	registered	_
33-8	5368-5370	to	_
33-9	5371-5374	the	_
33-10	5375-5381	nasion	_
33-11	5382-5385	and	_
33-12	5386-5398	preauricular	_
33-13	5399-5405	points	_
33-14	5406-5411	using	_
33-15	5412-5429	three-dimensional	_
33-16	5430-5442	digitization	_
33-17	5443-5452	equipment	_
33-18	5453-5454	(	_
33-19	5455-5463	Polhemus	_
33-20	5464-5473	FastTrack	_
33-21	5474-5475	)	_
33-22	5476-5477	.	_

Text=Participants sat upright in the MEG during the task.
34-1	5478-5490	Participants	_
34-2	5491-5494	sat	_
34-3	5495-5502	upright	_
34-4	5503-5505	in	_
34-5	5506-5509	the	_
34-6	5510-5513	MEG	_
34-7	5514-5520	during	_
34-8	5521-5524	the	_
34-9	5525-5529	task	_
34-10	5530-5531	.	_

Text=Continuous Head Position Indicator (cHPI) monitoring allowed for motion correction.
35-1	5532-5542	Continuous	_
35-2	5543-5547	Head	_
35-3	5548-5556	Position	_
35-4	5557-5566	Indicator	_
35-5	5567-5568	(	_
35-6	5569-5573	cHPI	_
35-7	5574-5575	)	_
35-8	5576-5586	monitoring	_
35-9	5587-5594	allowed	_
35-10	5595-5598	for	_
35-11	5599-5605	motion	_
35-12	5606-5616	correction	_
35-13	5617-5618	.	_

Text=Head position was checked between visits.
36-1	5619-5623	Head	_
36-2	5624-5632	position	_
36-3	5633-5636	was	_
36-4	5637-5644	checked	_
36-5	5645-5652	between	_
36-6	5653-5659	visits	_
36-7	5660-5661	.	_

Text=For the Rest10 task, average Euclidean distance between visits was 4.62 mm for HC and 6.06 mm for SZ.
37-1	5662-5665	For	_
37-2	5666-5669	the	_
37-3	5670-5676	Rest10	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
37-4	5677-5681	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
37-5	5682-5683	,	_
37-6	5684-5691	average	_
37-7	5692-5701	Euclidean	_
37-8	5702-5710	distance	_
37-9	5711-5718	between	_
37-10	5719-5725	visits	_
37-11	5726-5729	was	_
37-12	5730-5734	4.62	_
37-13	5735-5737	mm	_
37-14	5738-5741	for	_
37-15	5742-5744	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
37-16	5745-5748	and	_
37-17	5749-5753	6.06	_
37-18	5754-5756	mm	_
37-19	5757-5760	for	_
37-20	5761-5763	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
37-21	5764-5765	.	_

Text=For the Rest4 task, the distance was 4.90 mm for HC and 6.12 mm for SZ.
38-1	5766-5769	For	_
38-2	5770-5773	the	_
38-3	5774-5779	Rest4	_
38-4	5780-5784	task	_
38-5	5785-5786	,	_
38-6	5787-5790	the	_
38-7	5791-5799	distance	_
38-8	5800-5803	was	_
38-9	5804-5808	4.90	_
38-10	5809-5811	mm	_
38-11	5812-5815	for	_
38-12	5816-5818	HC	_
38-13	5819-5822	and	_
38-14	5823-5827	6.12	_
38-15	5828-5830	mm	_
38-16	5831-5834	for	_
38-17	5835-5837	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
38-18	5838-5839	.	_

Text=Head position consistency was similar between HC and SZ (all p ’ s> 0.31).
39-1	5840-5844	Head	_
39-2	5845-5853	position	_
39-3	5854-5865	consistency	_
39-4	5866-5869	was	_
39-5	5870-5877	similar	_
39-6	5878-5885	between	_
39-7	5886-5888	HC	_
39-8	5889-5892	and	_
39-9	5893-5895	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
39-10	5896-5897	(	_
39-11	5898-5901	all	_
39-12	5902-5903	p	_
39-13	5904-5905	’	_
39-14	5906-5907	s	_
39-15	5908-5909	>	_
39-16	5910-5914	0.31	_
39-17	5915-5916	)	_
39-18	5917-5918	.	_

Text=Structural MRI Data Acquisition Structural MRIs were obtained for mapping source locations.
40-1	5919-5929	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
40-2	5930-5933	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
40-3	5934-5938	Data	_
40-4	5939-5950	Acquisition	_
40-5	5951-5961	Structural	_
40-6	5962-5966	MRIs	_
40-7	5967-5971	were	_
40-8	5972-5980	obtained	_
40-9	5981-5984	for	_
40-10	5985-5992	mapping	_
40-11	5993-5999	source	_
40-12	6000-6009	locations	_
40-13	6010-6011	.	_

Text=Sagittal T1-weighted anatomical MR images were obtained using a Siemens TIM Trio 3 Tesla MRI system with a 32-channel head coil.
41-1	6012-6020	Sagittal	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-2	6021-6032	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-3	6033-6043	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-4	6044-6046	MR	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-5	6047-6053	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-6	6054-6058	were	_
41-7	6059-6067	obtained	_
41-8	6068-6073	using	_
41-9	6074-6075	a	_
41-10	6076-6083	Siemens	_
41-11	6084-6087	TIM	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-12	6088-6092	Trio	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-13	6093-6094	3	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-14	6095-6100	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-15	6101-6104	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-16	6105-6111	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-17	6112-6116	with	_
41-18	6117-6118	a	_
41-19	6119-6129	32-channel	_
41-20	6130-6134	head	_
41-21	6135-6139	coil	_
41-22	6140-6141	.	_

Text=Parameters of the multiecho 3D MPRAGE sequence were: TR/TE/TI = 2530/1.64, 3.5, 5.36, 7.22, 9.08/1200 ms, flip angle = 7°, field of view (FOV) = 256 mm x 256 mm, matrix = 256 × 256, 1 mm thick slice, 192 slices, GRAPPA acceleration = 2.
42-1	6142-6152	Parameters	_
42-2	6153-6155	of	_
42-3	6156-6159	the	_
42-4	6160-6169	multiecho	_
42-5	6170-6172	3D	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
42-6	6173-6179	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
42-7	6180-6188	sequence	_
42-8	6189-6193	were	_
42-9	6194-6195	:	_
42-10	6196-6204	TR/TE/TI	_
42-11	6205-6206	=	_
42-12	6207-6216	2530/1.64	_
42-13	6217-6218	,	_
42-14	6219-6222	3.5	_
42-15	6223-6224	,	_
42-16	6225-6229	5.36	_
42-17	6230-6231	,	_
42-18	6232-6236	7.22	_
42-19	6237-6238	,	_
42-20	6239-6248	9.08/1200	_
42-21	6249-6251	ms	_
42-22	6252-6253	,	_
42-23	6254-6258	flip	_
42-24	6259-6264	angle	_
42-25	6265-6266	=	_
42-26	6267-6269	7°	_
42-27	6270-6271	,	_
42-28	6272-6277	field	_
42-29	6278-6280	of	_
42-30	6281-6285	view	_
42-31	6286-6287	(	_
42-32	6288-6291	FOV	_
42-33	6292-6293	)	_
42-34	6294-6295	=	_
42-35	6296-6299	256	_
42-36	6300-6302	mm	_
42-37	6303-6304	x	_
42-38	6305-6308	256	_
42-39	6309-6311	mm	_
42-40	6312-6313	,	_
42-41	6314-6320	matrix	_
42-42	6321-6322	=	_
42-43	6323-6326	256	_
42-44	6327-6328	×	_
42-45	6329-6332	256	_
42-46	6333-6334	,	_
42-47	6335-6336	1	_
42-48	6337-6339	mm	_
42-49	6340-6345	thick	_
42-50	6346-6351	slice	_
42-51	6352-6353	,	_
42-52	6354-6357	192	_
42-53	6358-6364	slices	_
42-54	6365-6366	,	_
42-55	6367-6373	GRAPPA	_
42-56	6374-6386	acceleration	_
42-57	6387-6388	=	_
42-58	6389-6390	2	_
42-59	6391-6392	.	_

Text=MEG Data Preprocessing Raw MEG data were filtered for noise and corrected for head motion with the Neuromag Max-Filter 2.2 software using the temporal extension of signal space separation (t-SSS) method with movement compensation.
43-1	6393-6396	MEG	_
43-2	6397-6401	Data	_
43-3	6402-6415	Preprocessing	_
43-4	6416-6419	Raw	_
43-5	6420-6423	MEG	_
43-6	6424-6428	data	_
43-7	6429-6433	were	_
43-8	6434-6442	filtered	_
43-9	6443-6446	for	_
43-10	6447-6452	noise	_
43-11	6453-6456	and	_
43-12	6457-6466	corrected	_
43-13	6467-6470	for	_
43-14	6471-6475	head	_
43-15	6476-6482	motion	_
43-16	6483-6487	with	_
43-17	6488-6491	the	_
43-18	6492-6500	Neuromag	_
43-19	6501-6511	Max-Filter	_
43-20	6512-6515	2.2	_
43-21	6516-6524	software	_
43-22	6525-6530	using	_
43-23	6531-6534	the	_
43-24	6535-6543	temporal	_
43-25	6544-6553	extension	_
43-26	6554-6556	of	_
43-27	6557-6563	signal	_
43-28	6564-6569	space	_
43-29	6570-6580	separation	_
43-30	6581-6582	(	_
43-31	6583-6588	t-SSS	_
43-32	6589-6590	)	_
43-33	6591-6597	method	_
43-34	6598-6602	with	_
43-35	6603-6611	movement	_
43-36	6612-6624	compensation	_
43-37	6625-6626	.	_

Text=MEG data from each subject ’ s Visit 2 was transformed to Visit 1 head position using Maxfilter 2.2 MaxMove option to ensure equivalent sensor locations between visits.
44-1	6627-6630	MEG	_
44-2	6631-6635	data	_
44-3	6636-6640	from	_
44-4	6641-6645	each	_
44-5	6646-6653	subject	_
44-6	6654-6655	’	_
44-7	6656-6657	s	_
44-8	6658-6663	Visit	_
44-9	6664-6665	2	_
44-10	6666-6669	was	_
44-11	6670-6681	transformed	_
44-12	6682-6684	to	_
44-13	6685-6690	Visit	_
44-14	6691-6692	1	_
44-15	6693-6697	head	_
44-16	6698-6706	position	_
44-17	6707-6712	using	_
44-18	6713-6722	Maxfilter	_
44-19	6723-6726	2.2	_
44-20	6727-6734	MaxMove	_
44-21	6735-6741	option	_
44-22	6742-6744	to	_
44-23	6745-6751	ensure	_
44-24	6752-6762	equivalent	_
44-25	6763-6769	sensor	_
44-26	6770-6779	locations	_
44-27	6780-6787	between	_
44-28	6788-6794	visits	_
44-29	6795-6796	.	_

Text=No downsampling of the data was implemented at the preprocessing stage.
45-1	6797-6799	No	_
45-2	6800-6812	downsampling	_
45-3	6813-6815	of	_
45-4	6816-6819	the	_
45-5	6820-6824	data	_
45-6	6825-6828	was	_
45-7	6829-6840	implemented	_
45-8	6841-6843	at	_
45-9	6844-6847	the	_
45-10	6848-6861	preprocessing	_
45-11	6862-6867	stage	_
45-12	6868-6869	.	_

Text=Heartbeat and eye-blink artifacts were automatically detected and removed using signal space projection (SSP) in MNE software.
46-1	6870-6879	Heartbeat	_
46-2	6880-6883	and	_
46-3	6884-6893	eye-blink	_
46-4	6894-6903	artifacts	_
46-5	6904-6908	were	_
46-6	6909-6922	automatically	_
46-7	6923-6931	detected	_
46-8	6932-6935	and	_
46-9	6936-6943	removed	_
46-10	6944-6949	using	_
46-11	6950-6956	signal	_
46-12	6957-6962	space	_
46-13	6963-6973	projection	_
46-14	6974-6975	(	_
46-15	6976-6979	SSP	_
46-16	6980-6981	)	_
46-17	6982-6984	in	_
46-18	6985-6988	MNE	_
46-19	6989-6997	software	_
46-20	6998-6999	.	_

Text=The continuous data were segmented into artifact-free 2 second epochs.
47-1	7000-7003	The	_
47-2	7004-7014	continuous	_
47-3	7015-7019	data	_
47-4	7020-7024	were	_
47-5	7025-7034	segmented	_
47-6	7035-7039	into	_
47-7	7040-7053	artifact-free	_
47-8	7054-7055	2	_
47-9	7056-7062	second	_
47-10	7063-7069	epochs	_
47-11	7070-7071	.	_

Text=Epochs in which the magnetic field exceeded 5 pT were rejected.
48-1	7072-7078	Epochs	_
48-2	7079-7081	in	_
48-3	7082-7087	which	_
48-4	7088-7091	the	_
48-5	7092-7100	magnetic	_
48-6	7101-7106	field	_
48-7	7107-7115	exceeded	_
48-8	7116-7117	5	_
48-9	7118-7120	pT	_
48-10	7121-7125	were	_
48-11	7126-7134	rejected	_
48-12	7135-7136	.	_

Text=HC had 2.4% and SZ had 4.6% of all epochs rejected.
49-1	7137-7139	HC	_
49-2	7140-7143	had	_
49-3	7144-7147	2.4	_
49-4	7148-7149	%	_
49-5	7150-7153	and	_
49-6	7154-7156	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
49-7	7157-7160	had	_
49-8	7161-7164	4.6	_
49-9	7165-7166	%	_
49-10	7167-7169	of	_
49-11	7170-7173	all	_
49-12	7174-7180	epochs	_
49-13	7181-7189	rejected	_
49-14	7190-7191	.	_

Text=The total number of epochs used for further analysis included 401 EC, 402 EO epochs in HC, and 393 EC, 403 EO epochs in SZ.
50-1	7192-7195	The	_
50-2	7196-7201	total	_
50-3	7202-7208	number	_
50-4	7209-7211	of	_
50-5	7212-7218	epochs	_
50-6	7219-7223	used	_
50-7	7224-7227	for	_
50-8	7228-7235	further	_
50-9	7236-7244	analysis	_
50-10	7245-7253	included	_
50-11	7254-7257	401	_
50-12	7258-7260	EC	_
50-13	7261-7262	,	_
50-14	7263-7266	402	_
50-15	7267-7269	EO	_
50-16	7270-7276	epochs	_
50-17	7277-7279	in	_
50-18	7280-7282	HC	_
50-19	7283-7284	,	_
50-20	7285-7288	and	_
50-21	7289-7292	393	_
50-22	7293-7295	EC	_
50-23	7296-7297	,	_
50-24	7298-7301	403	_
50-25	7302-7304	EO	_
50-26	7305-7311	epochs	_
50-27	7312-7314	in	_
50-28	7315-7317	SZ	_
50-29	7318-7319	.	_

Text=The number of closed/open epochs did not differ between groups (all p ’ s> 0.25).
51-1	7320-7323	The	_
51-2	7324-7330	number	_
51-3	7331-7333	of	_
51-4	7334-7345	closed/open	_
51-5	7346-7352	epochs	_
51-6	7353-7356	did	_
51-7	7357-7360	not	_
51-8	7361-7367	differ	_
51-9	7368-7375	between	_
51-10	7376-7382	groups	_
51-11	7383-7384	(	_
51-12	7385-7388	all	_
51-13	7389-7390	p	_
51-14	7391-7392	’	_
51-15	7393-7394	s	_
51-16	7395-7396	>	_
51-17	7397-7401	0.25	_
51-18	7402-7403	)	_
51-19	7404-7405	.	_

Text=MEG Spectral Analyses For sensor analysis, we applied the summary spectral measures described in to simplify multi-channel MEG spectral data.
52-1	7406-7409	MEG	_
52-2	7410-7418	Spectral	_
52-3	7419-7427	Analyses	_
52-4	7428-7431	For	_
52-5	7432-7438	sensor	_
52-6	7439-7447	analysis	_
52-7	7448-7449	,	_
52-8	7450-7452	we	_
52-9	7453-7460	applied	_
52-10	7461-7464	the	_
52-11	7465-7472	summary	_
52-12	7473-7481	spectral	_
52-13	7482-7490	measures	_
52-14	7491-7500	described	_
52-15	7501-7503	in	_
52-16	7504-7506	to	_
52-17	7507-7515	simplify	_
52-18	7516-7529	multi-channel	_
52-19	7530-7533	MEG	_
52-20	7534-7542	spectral	_
52-21	7543-7547	data	_
52-22	7548-7549	.	_

Text=Using only planar gradiometers, the sensor array was divided into left and right equivalent regions, see Figure 2.
53-1	7550-7555	Using	_
53-2	7556-7560	only	_
53-3	7561-7567	planar	_
53-4	7568-7580	gradiometers	_
53-5	7581-7582	,	_
53-6	7583-7586	the	_
53-7	7587-7593	sensor	_
53-8	7594-7599	array	_
53-9	7600-7603	was	_
53-10	7604-7611	divided	_
53-11	7612-7616	into	_
53-12	7617-7621	left	_
53-13	7622-7625	and	_
53-14	7626-7631	right	_
53-15	7632-7642	equivalent	_
53-16	7643-7650	regions	_
53-17	7651-7652	,	_
53-18	7653-7656	see	_
53-19	7657-7663	Figure	_
53-20	7664-7665	2	_
53-21	7666-7667	.	_

Text=Spectral power was estimated using Matlab ’ s FFT function with a window size of 2048 for the following frequency bands: Delta (1–4 Hz), Theta (5–8 Hz), Alpha (9–13 Hz), Beta (14–29 Hz), and Gamma (31–58 Hz).
54-1	7668-7676	Spectral	_
54-2	7677-7682	power	_
54-3	7683-7686	was	_
54-4	7687-7696	estimated	_
54-5	7697-7702	using	_
54-6	7703-7709	Matlab	_
54-7	7710-7711	’	_
54-8	7712-7713	s	_
54-9	7714-7717	FFT	_
54-10	7718-7726	function	_
54-11	7727-7731	with	_
54-12	7732-7733	a	_
54-13	7734-7740	window	_
54-14	7741-7745	size	_
54-15	7746-7748	of	_
54-16	7749-7753	2048	_
54-17	7754-7757	for	_
54-18	7758-7761	the	_
54-19	7762-7771	following	_
54-20	7772-7781	frequency	_
54-21	7782-7787	bands	_
54-22	7788-7789	:	_
54-23	7790-7795	Delta	_
54-24	7796-7797	(	_
54-25	7798-7801	1–4	_
54-26	7802-7804	Hz	_
54-27	7805-7806	)	_
54-28	7807-7808	,	_
54-29	7809-7814	Theta	_
54-30	7815-7816	(	_
54-31	7817-7820	5–8	_
54-32	7821-7823	Hz	_
54-33	7824-7825	)	_
54-34	7826-7827	,	_
54-35	7828-7833	Alpha	_
54-36	7834-7835	(	_
54-37	7836-7840	9–13	_
54-38	7841-7843	Hz	_
54-39	7844-7845	)	_
54-40	7846-7847	,	_
54-41	7848-7852	Beta	_
54-42	7853-7854	(	_
54-43	7855-7860	14–29	_
54-44	7861-7863	Hz	_
54-45	7864-7865	)	_
54-46	7866-7867	,	_
54-47	7868-7871	and	_
54-48	7872-7877	Gamma	_
54-49	7878-7879	(	_
54-50	7880-7885	31–58	_
54-51	7886-7888	Hz	_
54-52	7889-7890	)	_
54-53	7891-7892	.	_

Text=Spectral measures included: power, normalized power, half-power, Shannon Spectral Entropy (SSE), and alpha reactivity.
55-1	7893-7901	Spectral	_
55-2	7902-7910	measures	_
55-3	7911-7919	included	_
55-4	7920-7921	:	_
55-5	7922-7927	power	_
55-6	7928-7929	,	_
55-7	7930-7940	normalized	_
55-8	7941-7946	power	_
55-9	7947-7948	,	_
55-10	7949-7959	half-power	_
55-11	7960-7961	,	_
55-12	7962-7969	Shannon	_
55-13	7970-7978	Spectral	_
55-14	7979-7986	Entropy	_
55-15	7987-7988	(	_
55-16	7989-7992	SSE	_
55-17	7993-7994	)	_
55-18	7995-7996	,	_
55-19	7997-8000	and	_
55-20	8001-8006	alpha	_
55-21	8007-8017	reactivity	_
55-22	8018-8019	.	_

Text=Normalized power was obtained by dividing the power within the frequency band by total 1–50 Hz power.
56-1	8020-8030	Normalized	_
56-2	8031-8036	power	_
56-3	8037-8040	was	_
56-4	8041-8049	obtained	_
56-5	8050-8052	by	_
56-6	8053-8061	dividing	_
56-7	8062-8065	the	_
56-8	8066-8071	power	_
56-9	8072-8078	within	_
56-10	8079-8082	the	_
56-11	8083-8092	frequency	_
56-12	8093-8097	band	_
56-13	8098-8100	by	_
56-14	8101-8106	total	_
56-15	8107-8111	1–50	_
56-16	8112-8114	Hz	_
56-17	8115-8120	power	_
56-18	8121-8122	.	_

Text=Half power was defined as the midpoint frequency where half of the power is below/above for the 1–50 Hz range and indicates overall spectral power shifts from low to high frequencies.
57-1	8123-8127	Half	_
57-2	8128-8133	power	_
57-3	8134-8137	was	_
57-4	8138-8145	defined	_
57-5	8146-8148	as	_
57-6	8149-8152	the	_
57-7	8153-8161	midpoint	_
57-8	8162-8171	frequency	_
57-9	8172-8177	where	_
57-10	8178-8182	half	_
57-11	8183-8185	of	_
57-12	8186-8189	the	_
57-13	8190-8195	power	_
57-14	8196-8198	is	_
57-15	8199-8210	below/above	_
57-16	8211-8214	for	_
57-17	8215-8218	the	_
57-18	8219-8223	1–50	_
57-19	8224-8226	Hz	_
57-20	8227-8232	range	_
57-21	8233-8236	and	_
57-22	8237-8246	indicates	_
57-23	8247-8254	overall	_
57-24	8255-8263	spectral	_
57-25	8264-8269	power	_
57-26	8270-8276	shifts	_
57-27	8277-8281	from	_
57-28	8282-8285	low	_
57-29	8286-8288	to	_
57-30	8289-8293	high	_
57-31	8294-8305	frequencies	_
57-32	8306-8307	.	_

Text=Alpha reactivity was calculated using normalized spectral power values with the following: (EC-EO) /EO.
58-1	8308-8313	Alpha	_
58-2	8314-8324	reactivity	_
58-3	8325-8328	was	_
58-4	8329-8339	calculated	_
58-5	8340-8345	using	_
58-6	8346-8356	normalized	_
58-7	8357-8365	spectral	_
58-8	8366-8371	power	_
58-9	8372-8378	values	_
58-10	8379-8383	with	_
58-11	8384-8387	the	_
58-12	8388-8397	following	_
58-13	8398-8399	:	_
58-14	8400-8401	(	_
58-15	8402-8407	EC-EO	_
58-16	8408-8409	)	_
58-17	8410-8413	/EO	_
58-18	8414-8415	.	_

Text=Global measures were the average of all regions and gradiometers.
59-1	8416-8422	Global	_
59-2	8423-8431	measures	_
59-3	8432-8436	were	_
59-4	8437-8440	the	_
59-5	8441-8448	average	_
59-6	8449-8451	of	_
59-7	8452-8455	all	_
59-8	8456-8463	regions	_
59-9	8464-8467	and	_
59-10	8468-8480	gradiometers	_
59-11	8481-8482	.	_

Text=For source analysis, the cortical surface of each participant was reconstructed from T1-weighted MRI files using FreeSurfer with a repeatedly subdivided octahedron as the spatial subsampling method, creating 4,098 locations per hemisphere with a source space of 4.9 mm.
60-1	8483-8486	For	_
60-2	8487-8493	source	_
60-3	8494-8502	analysis	_
60-4	8503-8504	,	_
60-5	8505-8508	the	_
60-6	8509-8517	cortical	_
60-7	8518-8525	surface	_
60-8	8526-8528	of	_
60-9	8529-8533	each	_
60-10	8534-8545	participant	_
60-11	8546-8549	was	_
60-12	8550-8563	reconstructed	_
60-13	8564-8568	from	_
60-14	8569-8580	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
60-15	8581-8584	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
60-16	8585-8590	files	_
60-17	8591-8596	using	_
60-18	8597-8607	FreeSurfer	_
60-19	8608-8612	with	_
60-20	8613-8614	a	_
60-21	8615-8625	repeatedly	_
60-22	8626-8636	subdivided	_
60-23	8637-8647	octahedron	_
60-24	8648-8650	as	_
60-25	8651-8654	the	_
60-26	8655-8662	spatial	_
60-27	8663-8674	subsampling	_
60-28	8675-8681	method	_
60-29	8682-8683	,	_
60-30	8684-8692	creating	_
60-31	8693-8698	4,098	_
60-32	8699-8708	locations	_
60-33	8709-8712	per	_
60-34	8713-8723	hemisphere	_
60-35	8724-8728	with	_
60-36	8729-8730	a	_
60-37	8731-8737	source	_
60-38	8738-8743	space	_
60-39	8744-8746	of	_
60-40	8747-8750	4.9	_
60-41	8751-8753	mm	_
60-42	8754-8755	.	_

Text=Source analysis was performed with MNE software using an anatomically constrained linear estimation inverse model known as dynamic statistical parametric mapping (dSPM).
61-1	8756-8762	Source	_
61-2	8763-8771	analysis	_
61-3	8772-8775	was	_
61-4	8776-8785	performed	_
61-5	8786-8790	with	_
61-6	8791-8794	MNE	_
61-7	8795-8803	software	_
61-8	8804-8809	using	_
61-9	8810-8812	an	_
61-10	8813-8825	anatomically	_
61-11	8826-8837	constrained	_
61-12	8838-8844	linear	_
61-13	8845-8855	estimation	_
61-14	8856-8863	inverse	_
61-15	8864-8869	model	_
61-16	8870-8875	known	_
61-17	8876-8878	as	_
61-18	8879-8886	dynamic	_
61-19	8887-8898	statistical	_
61-20	8899-8909	parametric	_
61-21	8910-8917	mapping	_
61-22	8918-8919	(	_
61-23	8920-8924	dSPM	_
61-24	8925-8926	)	_
61-25	8927-8928	.	_

Text=The regularization parameter corresponded with a signal-to-noise ratio of 3.
62-1	8929-8932	The	_
62-2	8933-8947	regularization	_
62-3	8948-8957	parameter	_
62-4	8958-8970	corresponded	_
62-5	8971-8975	with	_
62-6	8976-8977	a	_
62-7	8978-8993	signal-to-noise	_
62-8	8994-8999	ratio	_
62-9	9000-9002	of	_
62-10	9003-9004	3	_
62-11	9005-9006	.	_

Text=Source orientation had a loose constraint of 0.2.
63-1	9007-9013	Source	_
63-2	9014-9025	orientation	_
63-3	9026-9029	had	_
63-4	9030-9031	a	_
63-5	9032-9037	loose	_
63-6	9038-9048	constraint	_
63-7	9049-9051	of	_
63-8	9052-9055	0.2	_
63-9	9056-9057	.	_

Text=The forward solution was calculated with a single layer (inner skull) boundary element method.
64-1	9058-9061	The	_
64-2	9062-9069	forward	_
64-3	9070-9078	solution	_
64-4	9079-9082	was	_
64-5	9083-9093	calculated	_
64-6	9094-9098	with	_
64-7	9099-9100	a	_
64-8	9101-9107	single	_
64-9	9108-9113	layer	_
64-10	9114-9115	(	_
64-11	9116-9121	inner	_
64-12	9122-9127	skull	_
64-13	9128-9129	)	_
64-14	9130-9138	boundary	_
64-15	9139-9146	element	_
64-16	9147-9153	method	_
64-17	9154-9155	.	_

Text=The dSPM inverse model identified where the estimated current at each cortical surface vertex differed significantly from baseline noise (empty room data).
65-1	9156-9159	The	_
65-2	9160-9164	dSPM	_
65-3	9165-9172	inverse	_
65-4	9173-9178	model	_
65-5	9179-9189	identified	_
65-6	9190-9195	where	_
65-7	9196-9199	the	_
65-8	9200-9209	estimated	_
65-9	9210-9217	current	_
65-10	9218-9220	at	_
65-11	9221-9225	each	_
65-12	9226-9234	cortical	_
65-13	9235-9242	surface	_
65-14	9243-9249	vertex	_
65-15	9250-9258	differed	_
65-16	9259-9272	significantly	_
65-17	9273-9277	from	_
65-18	9278-9286	baseline	_
65-19	9287-9292	noise	_
65-20	9293-9294	(	_
65-21	9295-9300	empty	_
65-22	9301-9305	room	_
65-23	9306-9310	data	_
65-24	9311-9312	)	_
65-25	9313-9314	.	_

Text=Power spectral density (PSD) measures were computed from epochs using a multi-taper method with Discrete Prolate Spheroidal Sequence (DPSS) windows for each frequency band and region, using 7 tapers at 4 Hz and regions of interest based on the FreeSurfer DKT atlas.
66-1	9315-9320	Power	_
66-2	9321-9329	spectral	_
66-3	9330-9337	density	_
66-4	9338-9339	(	_
66-5	9340-9343	PSD	_
66-6	9344-9345	)	_
66-7	9346-9354	measures	_
66-8	9355-9359	were	_
66-9	9360-9368	computed	_
66-10	9369-9373	from	_
66-11	9374-9380	epochs	_
66-12	9381-9386	using	_
66-13	9387-9388	a	_
66-14	9389-9400	multi-taper	_
66-15	9401-9407	method	_
66-16	9408-9412	with	_
66-17	9413-9421	Discrete	_
66-18	9422-9429	Prolate	_
66-19	9430-9440	Spheroidal	_
66-20	9441-9449	Sequence	_
66-21	9450-9451	(	_
66-22	9452-9456	DPSS	_
66-23	9457-9458	)	_
66-24	9459-9466	windows	_
66-25	9467-9470	for	_
66-26	9471-9475	each	_
66-27	9476-9485	frequency	_
66-28	9486-9490	band	_
66-29	9491-9494	and	_
66-30	9495-9501	region	_
66-31	9502-9503	,	_
66-32	9504-9509	using	_
66-33	9510-9511	7	_
66-34	9512-9518	tapers	_
66-35	9519-9521	at	_
66-36	9522-9523	4	_
66-37	9524-9526	Hz	_
66-38	9527-9530	and	_
66-39	9531-9538	regions	_
66-40	9539-9541	of	_
66-41	9542-9550	interest	_
66-42	9551-9556	based	_
66-43	9557-9559	on	_
66-44	9560-9563	the	_
66-45	9564-9574	FreeSurfer	_
66-46	9575-9578	DKT	_
66-47	9579-9584	atlas	_
66-48	9585-9586	.	_

Text=PSD represents the average spectral power derived from each voxel time series for each regional label.
67-1	9587-9590	PSD	_
67-2	9591-9601	represents	_
67-3	9602-9605	the	_
67-4	9606-9613	average	_
67-5	9614-9622	spectral	_
67-6	9623-9628	power	_
67-7	9629-9636	derived	_
67-8	9637-9641	from	_
67-9	9642-9646	each	_
67-10	9647-9652	voxel	_
67-11	9653-9657	time	_
67-12	9658-9664	series	_
67-13	9665-9668	for	_
67-14	9669-9673	each	_
67-15	9674-9682	regional	_
67-16	9683-9688	label	_
67-17	9689-9690	.	_

Text=Global measures were data from all regional labels averaged.
68-1	9691-9697	Global	_
68-2	9698-9706	measures	_
68-3	9707-9711	were	_
68-4	9712-9716	data	_
68-5	9717-9721	from	_
68-6	9722-9725	all	_
68-7	9726-9734	regional	_
68-8	9735-9741	labels	_
68-9	9742-9750	averaged	_
68-10	9751-9752	.	_

Text=Normalized power was obtained by dividing the power within frequency band by the total 1–58 Hz power.
69-1	9753-9763	Normalized	_
69-2	9764-9769	power	_
69-3	9770-9773	was	_
69-4	9774-9782	obtained	_
69-5	9783-9785	by	_
69-6	9786-9794	dividing	_
69-7	9795-9798	the	_
69-8	9799-9804	power	_
69-9	9805-9811	within	_
69-10	9812-9821	frequency	_
69-11	9822-9826	band	_
69-12	9827-9829	by	_
69-13	9830-9833	the	_
69-14	9834-9839	total	_
69-15	9840-9844	1–58	_
69-16	9845-9847	Hz	_
69-17	9848-9853	power	_
69-18	9854-9855	.	_

Text=Functional network connectivity was estimated using a debiased estimator of the squared weighted phase lag index (wPLI-debiased).
70-1	9856-9866	Functional	_
70-2	9867-9874	network	_
70-3	9875-9887	connectivity	_
70-4	9888-9891	was	_
70-5	9892-9901	estimated	_
70-6	9902-9907	using	_
70-7	9908-9909	a	_
70-8	9910-9918	debiased	_
70-9	9919-9928	estimator	_
70-10	9929-9931	of	_
70-11	9932-9935	the	_
70-12	9936-9943	squared	_
70-13	9944-9952	weighted	_
70-14	9953-9958	phase	_
70-15	9959-9962	lag	_
70-16	9963-9968	index	_
70-17	9969-9970	(	_
70-18	9971-9984	wPLI-debiased	_
70-19	9985-9986	)	_
70-20	9987-9988	.	_

Text=The FNC measure, wPLI-debiased, detects true changes in phase-synchronization, while reducing the influence of common noise sources, changes in phase of coherency, and avoids spuriously increases by volume-conduction.
71-1	9989-9992	The	_
71-2	9993-9996	FNC	_
71-3	9997-10004	measure	_
71-4	10005-10006	,	_
71-5	10007-10020	wPLI-debiased	_
71-6	10021-10022	,	_
71-7	10023-10030	detects	_
71-8	10031-10035	true	_
71-9	10036-10043	changes	_
71-10	10044-10046	in	_
71-11	10047-10068	phase-synchronization	_
71-12	10069-10070	,	_
71-13	10071-10076	while	_
71-14	10077-10085	reducing	_
71-15	10086-10089	the	_
71-16	10090-10099	influence	_
71-17	10100-10102	of	_
71-18	10103-10109	common	_
71-19	10110-10115	noise	_
71-20	10116-10123	sources	_
71-21	10124-10125	,	_
71-22	10126-10133	changes	_
71-23	10134-10136	in	_
71-24	10137-10142	phase	_
71-25	10143-10145	of	_
71-26	10146-10155	coherency	_
71-27	10156-10157	,	_
71-28	10158-10161	and	_
71-29	10162-10168	avoids	_
71-30	10169-10179	spuriously	_
71-31	10180-10189	increases	_
71-32	10190-10192	by	_
71-33	10193-10210	volume-conduction	_
71-34	10211-10212	.	_

Text=It estimates the extent of observed phase leads and lags by the magnitude of the imaginary component of the cross-spectrum.
72-1	10213-10215	It	_
72-2	10216-10225	estimates	_
72-3	10226-10229	the	_
72-4	10230-10236	extent	_
72-5	10237-10239	of	_
72-6	10240-10248	observed	_
72-7	10249-10254	phase	_
72-8	10255-10260	leads	_
72-9	10261-10264	and	_
72-10	10265-10269	lags	_
72-11	10270-10272	by	_
72-12	10273-10276	the	_
72-13	10277-10286	magnitude	_
72-14	10287-10289	of	_
72-15	10290-10293	the	_
72-16	10294-10303	imaginary	_
72-17	10304-10313	component	_
72-18	10314-10316	of	_
72-19	10317-10320	the	_
72-20	10321-10335	cross-spectrum	_
72-21	10336-10337	.	_

Text=All data were exported to MATLAB (2018a, MathWorks) and run through custom scripts.
73-1	10338-10341	All	_
73-2	10342-10346	data	_
73-3	10347-10351	were	_
73-4	10352-10360	exported	_
73-5	10361-10363	to	_
73-6	10364-10370	MATLAB	_
73-7	10371-10372	(	_
73-8	10373-10378	2018a	_
73-9	10379-10380	,	_
73-10	10381-10390	MathWorks	_
73-11	10391-10392	)	_
73-12	10393-10396	and	_
73-13	10397-10400	run	_
73-14	10401-10408	through	_
73-15	10409-10415	custom	_
73-16	10416-10423	scripts	_
73-17	10424-10425	.	_

Text=Intraclass Correlation (ICC) ICC estimates and their 95% confidence intervals were calculated in SPSS to assess the between and within-subject variability using a two-way mixed effects model with absolute agreement, single measurement criteria, also known as ICC (3,1) model.
74-1	10426-10436	Intraclass	_
74-2	10437-10448	Correlation	_
74-3	10449-10450	(	_
74-4	10451-10454	ICC	_
74-5	10455-10456	)	_
74-6	10457-10460	ICC	_
74-7	10461-10470	estimates	_
74-8	10471-10474	and	_
74-9	10475-10480	their	_
74-10	10481-10483	95	_
74-11	10484-10485	%	_
74-12	10486-10496	confidence	_
74-13	10497-10506	intervals	_
74-14	10507-10511	were	_
74-15	10512-10522	calculated	_
74-16	10523-10525	in	_
74-17	10526-10530	SPSS	_
74-18	10531-10533	to	_
74-19	10534-10540	assess	_
74-20	10541-10544	the	_
74-21	10545-10552	between	_
74-22	10553-10556	and	_
74-23	10557-10571	within-subject	_
74-24	10572-10583	variability	_
74-25	10584-10589	using	_
74-26	10590-10591	a	_
74-27	10592-10599	two-way	_
74-28	10600-10605	mixed	_
74-29	10606-10613	effects	_
74-30	10614-10619	model	_
74-31	10620-10624	with	_
74-32	10625-10633	absolute	_
74-33	10634-10643	agreement	_
74-34	10644-10645	,	_
74-35	10646-10652	single	_
74-36	10653-10664	measurement	_
74-37	10665-10673	criteria	_
74-38	10674-10675	,	_
74-39	10676-10680	also	_
74-40	10681-10686	known	_
74-41	10687-10689	as	_
74-42	10690-10693	ICC	_
74-43	10694-10695	(	_
74-44	10696-10699	3,1	_
74-45	10700-10701	)	_
74-46	10702-10707	model	_
74-47	10708-10709	.	_

Text=ICCs were calculated for multiple rest iterations: for each visit (across one hour), for each task (across one week) and for all runs.
75-1	10710-10714	ICCs	_
75-2	10715-10719	were	_
75-3	10720-10730	calculated	_
75-4	10731-10734	for	_
75-5	10735-10743	multiple	_
75-6	10744-10748	rest	_
75-7	10749-10759	iterations	_
75-8	10760-10761	:	_
75-9	10762-10765	for	_
75-10	10766-10770	each	_
75-11	10771-10776	visit	_
75-12	10777-10778	(	_
75-13	10779-10785	across	_
75-14	10786-10789	one	_
75-15	10790-10794	hour	_
75-16	10795-10796	)	_
75-17	10797-10798	,	_
75-18	10799-10802	for	_
75-19	10803-10807	each	_
75-20	10808-10812	task	_
75-21	10813-10814	(	_
75-22	10815-10821	across	_
75-23	10822-10825	one	_
75-24	10826-10830	week	_
75-25	10831-10832	)	_
75-26	10833-10836	and	_
75-27	10837-10840	for	_
75-28	10841-10844	all	_
75-29	10845-10849	runs	_
75-30	10850-10851	.	_

Text=ICCs ranged from 0 to 1 (negative values scored as zero) with higher values indicating better reliability.
76-1	10852-10856	ICCs	_
76-2	10857-10863	ranged	_
76-3	10864-10868	from	_
76-4	10869-10870	0	_
76-5	10871-10873	to	_
76-6	10874-10875	1	_
76-7	10876-10877	(	_
76-8	10878-10886	negative	_
76-9	10887-10893	values	_
76-10	10894-10900	scored	_
76-11	10901-10903	as	_
76-12	10904-10908	zero	_
76-13	10909-10910	)	_
76-14	10911-10915	with	_
76-15	10916-10922	higher	_
76-16	10923-10929	values	_
76-17	10930-10940	indicating	_
76-18	10941-10947	better	_
76-19	10948-10959	reliability	_
76-20	10960-10961	.	_

Text=Following the guidelines of we defined ICCs as: excellent reliability> 0.75, good reliability 0.75–0.60, fair reliability 0.59–0.40, and poor reliability <0.40.
77-1	10962-10971	Following	_
77-2	10972-10975	the	_
77-3	10976-10986	guidelines	_
77-4	10987-10989	of	_
77-5	10990-10992	we	_
77-6	10993-11000	defined	_
77-7	11001-11005	ICCs	_
77-8	11006-11008	as	_
77-9	11009-11010	:	_
77-10	11011-11020	excellent	_
77-11	11021-11032	reliability	_
77-12	11033-11034	>	_
77-13	11035-11039	0.75	_
77-14	11040-11041	,	_
77-15	11042-11046	good	_
77-16	11047-11058	reliability	_
77-17	11059-11068	0.75–0.60	_
77-18	11069-11070	,	_
77-19	11071-11075	fair	_
77-20	11076-11087	reliability	_
77-21	11088-11097	0.59–0.40	_
77-22	11098-11099	,	_
77-23	11100-11103	and	_
77-24	11104-11108	poor	_
77-25	11109-11120	reliability	_
77-26	11121-11122	<	_
77-27	11123-11127	0.40	_
77-28	11128-11129	.	_

Text=Statistical Analysis All statistics were performed using SPSS (version 25 for Macintosh).
78-1	11130-11141	Statistical	_
78-2	11142-11150	Analysis	_
78-3	11151-11154	All	_
78-4	11155-11165	statistics	_
78-5	11166-11170	were	_
78-6	11171-11180	performed	_
78-7	11181-11186	using	_
78-8	11187-11191	SPSS	_
78-9	11192-11193	(	_
78-10	11194-11201	version	_
78-11	11202-11204	25	_
78-12	11205-11208	for	_
78-13	11209-11218	Macintosh	_
78-14	11219-11220	)	_
78-15	11221-11222	.	_

Text=Mixed Effect Repeated Measures-Analysis of Variance (RM-ANOVAs) had statistical thresholds set at p <0.05.
79-1	11223-11228	Mixed	_
79-2	11229-11235	Effect	_
79-3	11236-11244	Repeated	_
79-4	11245-11262	Measures-Analysis	_
79-5	11263-11265	of	_
79-6	11266-11274	Variance	_
79-7	11275-11276	(	_
79-8	11277-11286	RM-ANOVAs	_
79-9	11287-11288	)	_
79-10	11289-11292	had	_
79-11	11293-11304	statistical	_
79-12	11305-11315	thresholds	_
79-13	11316-11319	set	_
79-14	11320-11322	at	_
79-15	11323-11324	p	_
79-16	11325-11326	<	_
79-17	11327-11331	0.05	_
79-18	11332-11333	.	_

Text=Greenhouse-Geisser corrections were made for sphericity violations.
80-1	11334-11352	Greenhouse-Geisser	_
80-2	11353-11364	corrections	_
80-3	11365-11369	were	_
80-4	11370-11374	made	_
80-5	11375-11378	for	_
80-6	11379-11389	sphericity	_
80-7	11390-11400	violations	_
80-8	11401-11402	.	_

Text=The between-subject factor was Group (HC, SZ), within-subject factors included Hemisphere (Left, Right), Resting-State (EO, EC), and/or Region [Superior Parietal (SupPar), Inferior Parietal (InfPar), Precuneus] depending on measure explored.
81-1	11403-11406	The	_
81-2	11407-11422	between-subject	_
81-3	11423-11429	factor	_
81-4	11430-11433	was	_
81-5	11434-11439	Group	_
81-6	11440-11441	(	_
81-7	11442-11444	HC	_
81-8	11445-11446	,	_
81-9	11447-11449	SZ	_
81-10	11450-11451	)	_
81-11	11452-11453	,	_
81-12	11454-11468	within-subject	_
81-13	11469-11476	factors	_
81-14	11477-11485	included	_
81-15	11486-11496	Hemisphere	_
81-16	11497-11498	(	_
81-17	11499-11503	Left	_
81-18	11504-11505	,	_
81-19	11506-11511	Right	_
81-20	11512-11513	)	_
81-21	11514-11515	,	_
81-22	11516-11529	Resting-State	_
81-23	11530-11531	(	_
81-24	11532-11534	EO	_
81-25	11535-11536	,	_
81-26	11537-11539	EC	_
81-27	11540-11541	)	_
81-28	11542-11543	,	_
81-29	11544-11550	and/or	_
81-30	11551-11557	Region	_
81-31	11558-11559	[	_
81-32	11560-11568	Superior	_
81-33	11569-11577	Parietal	_
81-34	11578-11579	(	_
81-35	11580-11586	SupPar	_
81-36	11587-11588	)	_
81-37	11589-11590	,	_
81-38	11591-11599	Inferior	_
81-39	11600-11608	Parietal	_
81-40	11609-11610	(	_
81-41	11611-11617	InfPar	_
81-42	11618-11619	)	_
81-43	11620-11621	,	_
81-44	11622-11631	Precuneus	_
81-45	11632-11633	]	_
81-46	11634-11643	depending	_
81-47	11644-11646	on	_
81-48	11647-11654	measure	_
81-49	11655-11663	explored	_
81-50	11664-11665	.	_

Text=Significant interactions were followed-up with separate one-way ANOVAs, or t-tests on the factors of interest with familywise multiple comparisons correction using false discovery rate (FDR) correction with q=0.05.
82-1	11666-11677	Significant	_
82-2	11678-11690	interactions	_
82-3	11691-11695	were	_
82-4	11696-11707	followed-up	_
82-5	11708-11712	with	_
82-6	11713-11721	separate	_
82-7	11722-11729	one-way	_
82-8	11730-11736	ANOVAs	_
82-9	11737-11738	,	_
82-10	11739-11741	or	_
82-11	11742-11749	t-tests	_
82-12	11750-11752	on	_
82-13	11753-11756	the	_
82-14	11757-11764	factors	_
82-15	11765-11767	of	_
82-16	11768-11776	interest	_
82-17	11777-11781	with	_
82-18	11782-11792	familywise	_
82-19	11793-11801	multiple	_
82-20	11802-11813	comparisons	_
82-21	11814-11824	correction	_
82-22	11825-11830	using	_
82-23	11831-11836	false	_
82-24	11837-11846	discovery	_
82-25	11847-11851	rate	_
82-26	11852-11853	(	_
82-27	11854-11857	FDR	_
82-28	11858-11859	)	_
82-29	11860-11870	correction	_
82-30	11871-11875	with	_
82-31	11876-11882	q=0.05	_
82-32	11883-11884	.	_

